Examination of tumor mutations in varying risk categories showed that KRAS mutations were more prevalent in the high-risk subgroup than in the low-risk one.This suggests that the high-risk group is more aggressive and less responsive to treatment, leading to a poorer prognosis. The gene discussed is KRAS; the disease is neoplasm.